Eli Lilly and Co.'s Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura in adults has received approval from the U.S. Food and Drug Administration (FDA).
"Reyvow is a new option for the acute treatment of migraine, a painful condition that affects one in seven Americans,"Nick Kozauer, M.D., acting deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a press release. "We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine."
The efficacy of Reyvow has been studied in 3,177 adult patients with a history of migraine with and without aura. The percentages of patients whose pain resolved and whose migraine symptoms such as nausea, light sensitivity or sound sensitivity resolved two hours after treatment, were significantly greater among patients receiving Reyvow at all doses compared to those receiving a placebo.
Reyvow is not indicated for the preventive treatment of migraine.